keyword
MENU ▼
Read by QxMD icon Read
search

Folfox

keyword
https://www.readbyqxmd.com/read/28816286/-prognostic-value-of-chemotherapy-induced-neutropenia-in-metastatic-colon-cancer-patients-undergoing-first-line-chemotherapy-with-folfox
#1
Y Chen, Y R Wang, Y Shi, G H Dai
OBJECTIVE: To evaluate the prognostic value of chemotherapy-induced neutropenia (CIN) in metastatic colon cancer undergoing first-line chemotherapy with FOLFOX. METHODS: Data were collected from a retrospective survey of 158 consecutive metastatic colon cancer patients who had undergone FOLFOX chemotherapy. The clinicopathological characteristics and chemotherapy features of the patients were analyzed as potential prognostic factors. The patients were stratified by the decreased level of CIN to three groups: large decreased level (the number of neutrophil decreased more than 1...
August 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28800321/the-impact-of-chemotherapy-associated-hemoglobin-on-prognosis-of-colorectal-cancer-patients-receiving-adjuvant-chemotherapy
#2
Yi-Sheng Wei, Ya-Guang Zhou, Guo-Ying Wang, Zhi-Hua Liang, Min-Rui Luo, Tian-Ai Yang, Jun Huang
BACKGROUND AND OBJECTIVE: The association of chemotherapy-associated hemoglobin and survival of colorectal cancer (CRC) receiving adjuvant chemotherapy is uncertain. We sought to explore the prognostic value of chemotherapy-associated hemoglobin in CRC receiving adjuvant chemotherapy and the best cut point affecting prognosis. METHODS: Three hundred and twenty stage II and III CRC patients receiving adjuvant FOLFOX chemotherapy from March 2003 to March 2012 were enrolled...
August 1, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/28798979/mucosa-associated-invariant-t-cells-infiltrate-hepatic-metastases-in-patients-with-colorectal-carcinoma-but-are-rendered-dysfunctional-within-and-adjacent-to-tumor-microenvironment
#3
Christopher R Shaler, Mauro E Tun-Abraham, Anton I Skaro, Khashayarsha Khazaie, Alexandra J Corbett, Tina Mele, Roberto Hernandez-Alejandro, S M Mansour Haeryfar
Mucosa-associated invariant T (MAIT) cells are innate-like T lymphocytes that are unusually abundant in the human liver, a common site of colorectal carcinoma (CRC) metastasis. However, whether they contribute to immune surveillance against colorectal liver metastasis (CRLM) is essentially unexplored. In addition, whether MAIT cell functions can be impacted by chemotherapy is unclear. These are important questions given MAIT cells' potent immunomodulatory and inflammatory properties. Herein, we examined the frequencies and functions of peripheral blood, healthy liver tissue, tumor-margin and tumor-infiltrating MAIT cells in 21 CRLM patients who received no chemotherapy, FOLFOX, or a combination of FOLFOX and Avastin before they underwent liver resection...
August 10, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28781171/first-line-selective-internal-radiotherapy-plus-chemotherapy-versus-chemotherapy-alone-in-patients-with-liver-metastases-from-colorectal-cancer-foxfire-sirflox-and-foxfire-global-a-combined-analysis-of-three-multicentre-randomised-phase-3-trials
#4
Harpreet S Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Guy van Hazel, Ricky A Sharma
BACKGROUND: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastatic colorectal cancer with liver metastases. The studies were designed for combined analysis of overall survival...
August 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28771807/combination-adjuvant-chemotherapy-with-targeted-drugs-for-treatment-of-colorectal-cancer-a-network-meta-analysis
#5
Jinghui Wang, Li Luo, Dingxue Wang, Bin Guo, Jun Li, Zhu Yang, Dongxin Tang
BACKGROUND: Colorectal cancer (CRC) is one of the most fatal diseases in the world. The efficacy of present chemotherapy treatments are limited and the addition of targeted drugs have been put into practice. However, the preferred treatments among adjuvant chemotherapies still remain controversial and uncertain. OBJECTIVE: To evaluate the efficacy of different adjuvant chemotherapies combined with or without targeted drugs to determine the optimal treatment for patients with CRC in clinical practice...
August 3, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28746914/a-phase-i-clinical-trial-of-binimetinib-in-combination-with-folfox-in-patients-with-advanced-metastatic-colorectal-cancer-who-failed-prior-standard-therapy
#6
May Cho, Jun Gong, Paul Frankel, Timothy W Synold, Dean Lim, Vincent Chung, Joseph Chao, Daneng Li, Yuan Chen, Stephen Sentovich, Kurt Melstrom, Gagandeep Singh, Eloise Luevanos, Marwan Fakih
BACKGROUND: This was a first in-human, open-label, dose-escalation phase I study conducted to evaluate the maximum tolerated dose (MTD), safety, and efficacy of the combination of oral binimetinib and FOLFOX. MATERIALS AND METHODS: Patients with metastatic colorectal cancer (mCRC) who progressed on prior standard therapies received twice daily binimetinib continuously or intermittently with FOLFOX. Dose-limiting toxicities (DLTs) were assessed in the first 2 cycles of study treatment...
July 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28742687/the-allosteric-hemoglobin-effector-itpp-inhibits-metastatic-colon-cancer-in-mice
#7
Perparim Limani, Michael Linecker, Marcel A Schneider, Philipp Kron, Christoph Tschuor, Ekaterina Kachaylo, Udo Ungethuem, Claude Nicolau, Jean-Marie Lehn, Rolf Graf, Bostjan Humar, Pierre-Alain Clavien
OBJECTIVE: To test the effects of enhanced intracellular oxygen contents on the metastatic potential of colon cancer. BACKGROUND: Colorectal cancer is the commonest gastrointestinal carcinoma. Distant metastases occur in half of patients and are responsible for most cancer-related deaths. Tumor hypoxia is central to the pathogenesis of metastases. Myo-Inositoltrispyrophosphate (ITPP), a nontoxic, antihypoxic compound, has recently shown significant benefits in experimental cancer, particularly when combined with standard chemotherapy...
July 24, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28735067/treatment-sequence-with-either-irinotecan-cetuximab-followed-by-folfox-4-or-the-reverse-strategy-in-metastatic-colorectal-cancer-patients-progressing-after-first-line-folfiri-bevacizumab-an-italian-group-for-the-study-of-gastrointestinal-cancer-phase-iii-randomised
#8
Stefano Cascinu, Gerardo Rosati, Guglielmo Nasti, Sara Lonardi, Alberto Zaniboni, Paolo Marchetti, Francesco Leone, Domenico Bilancia, Rosario Vincenzo Iaffaioli, Vittorina Zagonel, Monica Giordano, Domenico C Corsi, Francesco Ferraú, Roberto Labianca, Monica Ronzoni, Mario Scartozzi, Francesca Galli
INTRODUCTION: The optimal treatment strategy for RAS wild type (WT) mCRC is controversial. Our phase III study investigated the effect of introducing earlier (second-line) or later (third-line) cetuximab in patients progressed after FOLFIRI/bevacizumab first-line. PATIENTS AND METHODS: mCRC patients progressing after FOLFIRI/bevacizumab first-line were randomised to receive second-line irinotecan/cetuximab followed by third-line FOLFOX-4 (arm A) or the reverse sequence (arm B)...
July 20, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28714378/utilization-of-capecitabine-plus-oxaliplatin-and-5-fluorouracil-folinic-acid-plus-oxaliplatin-in-the-adjuvant-treatment-of-stage-iib-and-stage-iii-colon-cancer-a-multi-centre-retrospective-chart-review-study
#9
Aaron Sha, Shirin Abadi, Sharlene Gill
Purpose First, to assess drug utilization rates of capecitabine plus oxaliplatin (CAPOX) versus 5-fluorouracil plus oxaliplatin (mFOLFOX6) regimens in the treatment of stage IIB and stage III colon cancer. Second, to assess patient characteristics used to select CAPOX versus FOLFOX therapy, dose-limiting toxicities, dose intensities and treatment completion rates. Methods Patients with resected stage IIB or stage III colon cancer from five British Columbia Cancer Agency centres treated with CAPOX or mFOLFOX6 were selected for the analysis...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28707088/prognostic-significance-of-lymphocyte-counts-in-colon-cancer-patients-treated-with-folfox-chemotherapy
#10
O Kyu Noh, Seung Yeop Oh, Young Bae Kim, Kwang Wook Suh
PURPOSE: There is increasing interest in immune function in combination with chemotherapy for cancer treatment. However, the effects of chemotherapy on the human immune system remain to be determined. The aim of this study was to investigate the prognostic impact of lymphocyte and neutrophil counts in colon cancer patients who were treated with curative surgery and adjuvant chemotherapy. METHODS: Two hundred thirty-one patients with colon cancers who underwent curative surgery and FOLFOX adjuvant chemotherapy between November 2005 and December 2011 were included...
July 13, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28702417/folfox-encephalopathy-a-rare-case-series
#11
Ullas Batra, Venkata Pradeep Babu Koyyala, Akhil Jain, Chaturbhuj Agrawal, Udip Maheswari
No abstract text is available yet for this article.
April 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28696176/interstitial-lung-disease-following-folfox-folfiri-and-bevacizumab-therapy-associated-with-leucovorin-a-case-report
#12
Satoru Mitsuboshi, Hiromi Kozakai, Hitoshi Yamada, Kazuhiko Nagai, Tomoyasu Furukawa, Kikuo Aizawa
Chemotherapy-induced interstitial lung disease in colorectal cancer patients is rare but represents a life-threatening adverse reaction. We report here a case of interstitial lung disease following chemotherapy for metastatic colorectal cancer and the interesting results of the drug-induced lymphocyte stimulation test and leukocyte migration test. After chemotherapy with oxaliplatin plus infusional 5-fluorouracil and leucovorin (FOLFOX) plus bevacizumab followed by irinotecan plus infusional 5-fluorouracil and leucovorin (FOLFIRI), the patient was hospitalized with fever and chills...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28693229/micrornas-as-outcome-predictors-in-patients-with-metastatic-colorectal-cancer-treated-with-bevacizumab-in-combination-with-folfox
#13
I Kiss, J Mlčochová, K Součková, P Fabian, A Poprach, J Halamkova, M Svoboda, R Vyzula, O Slaby
Bevacizumab is a humanized anti-vascular endothelial growth factor monoclonal antibody, used in combination with a oxaliplatin-based chemotherapy in the treatment of metastatic colorectal cancer (mCRC). The aim of the present study was to identify microRNA (miRNA)-based predictive biomarkers of therapy response in order to avoid unnecessary and costly therapy to non-responding patients. High-throughput miRNA microarray profiling (Affymetrix miRNA array) was performed on a discovery cohort of patients with mCRC...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28687025/prognostic-value-of-positron-emission-tomography-computed-tomography-for-adjuvant-chemotherapy-of-colon-cancer
#14
HyungJoo Baik, Seok Mo Lee, Sang Hyuk Seo, Min Sung An, Kwang Hee Kim, Ki Beom Bae, Min Kyung Oh, Kwan Hee Hong
BACKGROUND: To assess the prognostic value of preoperative (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-risk stage II or stage III colon cancer who underwent FOLFOX chemotherapy. METHODS: The study included 166 patients with high-risk stage II or stage III colon cancer who received FOLFOX4 chemotherapy. Retrospective patient data were analysed including pathological stage, histology, disease-free survival (DFS) and the maximum standardized uptake value (SUVmax ) of the primary tumour on (18) F-fluorodeoxyglucose positron emission tomography/computed tomography...
July 7, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28682222/the-clinical-effectiveness-and-cost-effectiveness-of-cetuximab-review-of-technology-appraisal-no-176-and-panitumumab-partial-review-of-technology-appraisal-no-240-for-previously-untreated-metastatic-colorectal-cancer-a-systematic-review-and-economic-evaluation
#15
Nicola Huxley, Louise Crathorne, Jo Varley-Campbell, Irina Tikhonova, Tristan Snowsill, Simon Briscoe, Jaime Peters, Mary Bond, Mark Napier, Martin Hoyle
BACKGROUND: Colorectal cancer is the fourth most commonly diagnosed cancer in the UK after breast, lung and prostate cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy. Targeted agents are available, including the antiepidermal growth factor receptor (EGFR) agents cetuximab (Erbitux(®), Merck Serono UK Ltd, Feltham, UK) and panitumumab (Vecitibix(®), Amgen UK Ltd, Cambridge, UK). OBJECTIVE: To investigate the clinical effectiveness and cost-effectiveness of panitumumab in combination with chemotherapy and cetuximab in combination with chemotherapy for rat sarcoma (RAS) wild-type (WT) patients for the first-line treatment of metastatic colorectal cancer...
June 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28668762/mangafodipir-a-selective-cytoprotectant-with-special-reference-to-oxaliplatin-and-its-association-to-chemotherapy-induced-peripheral-neuropathy-cipn
#16
REVIEW
Jan Olof G Karlsson, Rolf Gg Andersson, Per Jynge
Oxaliplatin, in combination with 5-fluorouracil plus folinate (or capecitabine), has increased survival substantially in stage III colorectal cancer and prolonged life in stage IV patients, but its use is compromised because of severe toxicity. Chemotherapy-induced peripheral neuropathy (CIPN) is the most problematic dose-limiting toxicity of oxaliplatin. Oncologists included for years calcium and magnesium infusion as part of clinical practice for preventing CIPN. Results from a phase III prospective study published in 2014, however, overturned this practice...
August 2017: Translational Oncology
https://www.readbyqxmd.com/read/28662341/a-phase-ii-study-of-the-c-met-inhibitor-tivantinib-in-combination-with-folfox-for-the-treatment-of-patients-with-previously-untreated-metastatic-adenocarcinoma-of-the-distal-esophagus-gastroesophageal-junction-or-stomach
#17
Shubham Pant, Manish Patel, Carla Kurkjian, Brian Hemphill, Maria Flores, Dana Thompson, Johanna Bendell
BACKGROUND: This phase I/II study was designed to determine the maximum tolerated dose of tivantinib in combination with standard dose FOLFOX for the treatment of patients with advanced solid tumors and to evaluate the safety and efficacy of this combination for patients with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach. METHODS: Patients with advanced solid tumors for which FOLFOX would be appropriate chemotherapy received escalating doses of tivantinib BID (days 1-14) in a standard 3 + 3 design in phase I...
June 29, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28651158/prospective-validation-of-a-lymphocyte-infiltration-prognostic-test-in-stage-iii-colon-cancer-patients-treated-with-adjuvant-folfox
#18
Jean-François Emile, Catherine Julié, Karine Le Malicot, Come Lepage, Josep Tabernero, Enrico Mini, Gunnar Folprecht, Jean-Luc Van Laethem, Stéphanie Dimet, Camille Boulagnon-Rombi, Marc-Antoine Allard, Frédérique Penault-Llorca, Jaafar Bennouna, Pierre Laurent-Puig, Julien Taieb
BACKGROUND: The prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is currently available for clinical practice. We previously described an automated and reproducible method for testing LI and aimed to validate it for clinical use. PATIENTS AND METHODS: According to National Institutes of Health criteria, we designed a prospective validation of this biomarker in patients included in the PETACC8 phase III study...
June 23, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28649886/epidermal-growth-factor-inhibitors-in-first-line-for-metastatic-colorectal-cancer-with-ras-wild-type-a-perspective-based-on-pharmacological-costs
#19
Jacopo Giuliani, Andrea Bonetti
In light of the relevant expenses of pharmacological interventions it might be interesting to make a balance between the cost of the new drugs administered, such as EGFRIs (cetuximab and panitunumab) and the added value represented by the improvement of the clinical parameters of interest such as progression free survival (PFS). Areas covered: The analysis was conducted to assess the effect of front-line chemotherapy on the PFS, separately, on each arm of the evaluated trials. Only phase III randomized controlled trials (RCTs) were considered...
June 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28636554/proton-pump-inhibitors-increase-the-chemosensitivity-of-patients-with-advanced-colorectal-cancer
#20
Xiaoyu Wang, Chun Liu, Jiaqi Wang, Yue Fan, Zhenghua Wang, Yuanyuan Wang
Changes in pH can alter the uptake of chemotherapy drugs. Proton pump inhibitors (PPIs) may therefore increase the chemosensitivity of cancer cells and cytotoxicity of chemotherapeutic drugs by increasing their uptake. We investigated the chemosensitizing potential of PPIs in colorectal cancer (CRC). Our in vitro data show that the PPI pantoprazole increases the chemosensitivity of CRC HT29 and RKO cells to fluorouracil (5-FU). Our in vivo data demonstrate that pantoprazole also increases the ability of 5-FU to inhibit CRC tumor growth in mice...
June 16, 2017: Oncotarget
keyword
keyword
2273
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"